Overview
The goal of this study is to evaluate short course radiation in the post-operative female pelvis after hysterectomy in stage III-IVA endometrial adenocarcinoma patients, or any stage patients with uterine serous or carcinosarcoma histology. The investigators hypothesize that short course pelvic radiation will have an acute and late grade 3-4 toxicity rate < 10%, and patients will benefit from both convenient and effective loco-regional control comparable to the traditional 5-6 weeks of radiation.
Eligibility
Inclusion Criteria:
- Histologically or cytologically confirmed stage IIIA-IV endometrial cancer, or any stage with uterine serous or carcinosarcoma histology.
- Must have already undergone radical hysterectomy. Hysterectomy may have occurred no more than one year prior to enrollment.
- At least 18 years of age.
- ECOG performance status 2
- Minimal bone marrow and organ function as defined below:
- Leukocytes 1,000 K/cumm
- Absolute neutrophil count 500 K/cumm
- Platelets 50,000 K/cumm
- Hemoglobin 7g/dL
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- Prior radiation to the pelvis.
- Currently receiving any investigational agents.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, inflammatory bowel disease, or irritable bowel disease.
- Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.